• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nanexa

4.45 SEK

+1.37 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.37 %
+23.44 %
+17.41 %
0.00 %
+149.72 %
+119.75 %
+26.42 %
-13.10 %
-45.60 %

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Read more
Market cap
850.11M SEK
Turnover
1.37M SEK
Revenue
36.15M
EBIT %
-24.26 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

Regulatory press release5/12/2026, 3:00 PM

Kommuniké från årsstämma i Nanexa AB

Nanexa
Regulatory press release5/12/2026, 3:00 PM

Bulletin from the Annual General Meeting of Nanexa AB

Nanexa
Third party research4/30/2026, 6:22 AM

Nanexa: Strong semaglutide data and reinforced funding extend strategic runway - Emergers

Following the license agreement with Moderna in Q4’25, Nanexa continues to advance along three parallel value tracks: the Moderna collaboration, additional PharmaShell license deals and the internally developed long-acting semaglutide program. Q1’26 ...

Nanexa

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/29/2026, 6:00 AM

Nanexa publicerar delårsrapport för januari-mars 2026

Nanexa
Regulatory press release4/29/2026, 6:00 AM

Nanexa publishes interim report for January-March 2026

Nanexa
Regulatory press release4/28/2026, 4:55 PM

Nanexa beslutar om kvittning av utestående lån

Nanexa
Regulatory press release4/28/2026, 4:55 PM

Nanexa resolves on set-off of outstanding loan

Nanexa
Regulatory press release4/8/2026, 6:01 AM

Kallelse till årsstämma i Nanexa AB (publ)

Nanexa
Regulatory press release4/8/2026, 6:01 AM

Notice of annual general meeting in Nanexa AB (publ)

Nanexa
Press release4/2/2026, 6:00 AM

Nanexa informerar om nyttjande av teckningsoptioner

Nanexa
Press release4/2/2026, 6:00 AM

Nanexa announces exercise of warrants

Nanexa
Regulatory press release3/26/2026, 7:01 AM

Nanexa publicerar årsredovisning för 2025

Nanexa
Regulatory press release3/26/2026, 7:01 AM

Nanexa publishes annual report for 2025

Nanexa
Press release3/19/2026, 7:59 AM

Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell®

Nanexa
Press release3/19/2026, 7:59 AM

Nanexa visar möjligheten till kvartalsvis dosering av semaglutid med PharmaShell®

Nanexa
Press release2/24/2026, 7:15 AM

Valberedning inför årsstämman 2026 i Nanexa AB (publ)

Nanexa
Press release2/24/2026, 7:15 AM

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

Nanexa
Third party research2/20/2026, 7:41 AM

Nanexa: Funding secured as semaglutide pivot sharpens commercial focus - Emergers

Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to leverage its PharmaShell technology into commercial value creation: the Moderna license development agreement ...

Nanexa
Regulatory press release2/19/2026, 7:01 AM

Nanexa publicerar bokslutskommuniké och Q4-rapport 2025

Nanexa
Regulatory press release2/19/2026, 7:01 AM

Nanexa publishes year-end report and Q4 report 2025

Nanexa